Shanghai RAAS Blood Products: Announcement on the Cancellation of the Remaining Repurchased Shares, the Reduction of Registered Capital, and the Corresponding Amendment of the Company's Articles of Association.
Shanghai RAAS Blood Products: Announcement on granting reserved shares of the first employee stock ownership plan to some employees
Shanghai RAAS Blood Products: Supplementary Announcement Regarding the Board of Directors Election
Shanghai RAAS Blood Products: Supplementary Announcement Regarding the Election of the Supervisory Board
Shanghai RAAS Blood Products: Notice Regarding the Holding of the Second Extraordinary Shareholders' Meeting in 2024.
Shanghai RAAS Blood Products: Supplementary notice on the election of the Supervisory Board.
Shanghai RAAS Blood Products: Supplementary announcement on the election of the board of directors.
Shanghai RAAS Blood Products: Announcement regarding the signing of the Exclusive Strategic Cooperation Agreement between the company and its affiliates.
Shanghai RAAS Blood Products: Announcement regarding the signing of the 9th revised exclusive agency agreement between the company and its affiliates.
Shanghai RAAS Blood Products: Legal Opinion of Beijing Zhonglun (Shanghai) Law Firm on the 2023 Annual General Meeting of Shareholders of Shanghai Laishi Blood Products Co., Ltd.
Shanghai RAAS Blood Products: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Shanghai RAAS Blood Products: Shareholder return plan for the next three years (2024-2026)
Shanghai RAAS Blood Products: Notice of Annual General Meeting of Shareholders
Shanghai RAAS Blood Products: Internal Control Self-Assessment Report
Shanghai RAAS Blood Products: Explanation of Grifols Diagnostic Solutions, Inc.'s achievement of its 2019-2023 performance commitments
Shanghai RAAS Blood Products: 2023 Financial Results Report
Shanghai RAAS Blood Products: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Shanghai RAAS Blood Products: Announcement on the 2024 Mid-Term Profit Distribution Plan
Shanghai RAAS Blood Products: Special instructions for securities investment
Shanghai Laishi: Announcement on the change of quality control reviewers in accounting firms
No Data